Business, energy, technology, markets and global industry news from Business News Today

U.S. Food and Drug Administration

PharmaDeviceNews U.S. Food and Drug Administration
Representative image of Parkinson’s disease research as BioVie’s bezisterim shows promising Phase 2 improvements in motor and non-motor symptoms among patients with elevated inflammation.
Pharma & Biotech

Bezisterim Phase 2 results highlight potential new treatment approach for Parkinson’s disease symptoms

BioVie's bezisterim shows promising Phase 2 Parkinson's results in patients with elevated inflammation. Explore the findings and Phase 3 outlook.

Read More
Representative image of bipolar disorder clinical research as Rapport Therapeutics’ RAP-219 meets key Phase 2 trial endpoints, showing promising results in bipolar mania treatment.
Pharma & Biotech

Rapport Therapeutics’ RAP-219 delivers statistically significant bipolar mania improvements in Phase 2 trial

Rapport Therapeutics' RAP-219 meets Phase 2 bipolar mania endpoints. Explore its clinical results, safety findings and planned Phase 3 trials.

Read More
Representative image of osteoporosis research as Entera Bio’s oral drug EB613 shows promising Phase 2 bone density gains ahead of a planned Phase 3 trial.
Pharma & Biotech

EB613 oral osteoporosis treatment gains momentum as Entera Bio outlines 900-patient Phase 3 trial

Entera Bio reports stronger EB613 bone density gains in Phase 2 osteoporosis analysis. Explore the results and upcoming Phase 3 trial plans.

Read More
Pharma & Biotech

Can Alpha Cognition’s new manufacturing process strengthen ZUNVEYL market protection?

Alpha Cognition publishes a ZUNVEYL manufacturing patent application as sales grow, targeting process protection through 2045.

Read More
Pharma & Biotech

Can Zydus saroglitazar compete with Iqirvo and Livdelzi in the US PBC market?

Zydus saroglitazar shows 60.7% US biochemical response in PBC as its November 27 FDA decision approaches. Examine the Phase 3 evidence.

Read More
AstraZeneca is expanding Trixeo Aerosphere beyond chronic obstructive pulmonary disease into uncontrolled asthma across Europe for patients aged 12 years and older. Representative image.
Medical Devices & Diagnostics

An implant for severe asthma? Spiro Medical begins testing spinal nerve stimulation beyond drugs

Spiro Medical implants its first PULSAR asthma patient as a 30-person study tests spinal nerve stimulation for severe, uncontrolled asthma.

Read More
Mezzion’s investigational drug udenafil has reduced kidney cyst burden in an ADPKD animal study, strengthening the scientific rationale for the company’s planned Phase 2b clinical programme. Representative image.
Pharma & Biotech

Keenova’s TERLIVAZ shows kidney response in transplant-ineligible patients as new CONFIRM analysis emerges

Keenova's TERLIVAZ analysis examines kidney recovery in transplant-ineligible HRS-AKI patients as respiratory safety and survival remain key concerns.

Read More
Pharma & Biotech

Catalent is entering unit-dose OTC gels with Mantra. Can medicine in a pouch challenge pills?

Catalent will manufacture Mantra's single-serve OTC gels for sleep, pain and menstrual relief. See what the deal means for drug delivery and supply.

Read More
Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.
Pharma & Biotech

Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone

Bristol Myers Squibb's RYZ101 meets its Phase 3 endpoint after lutetium-177 treatment, advancing alpha radiopharmaceutical development.

Read More
Medtronic’s Affera Mapping and Ablation System with the Sphere-9 catheter has gained an expanded European CE Mark for ventricular arrhythmias, extending its integrated mapping, pulsed-field and radiofrequency ablation workflow into ventricular procedures. Representative image.
Medical Devices & Diagnostics

Why Thermedical’s Durablate catheter could address difficult-to-reach heart arrhythmias

Thermedical names nine experts to oversee pivotal SERF ablation testing after promising early results. Safety and six-month recurrence remain key tests.

Read More